약물군-약물군 조합으로 도출한 약력학적 기전의 추가 병용금기성분
Pharmacodynamic Drug-Drug Interactions Considered to be Added in the List of Contraindications with Pharmacological Classification in Korea
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: Drug utilization review program in Korea has provided ‘drug combinations to avoid (DCA)’ alerts to physicians and pharmacists to prevent potential adverse drug events or inappropriate drug use. Seven hundred and six DCA pairs have been announced officially by the Ministry of Food and Drug Safety (MFDS) by March, 2015. Some DCA pairs could be grouped based on the drug interaction mechanism and its consequences. This study aimed to investigate the drug-drug interaction (DDI) pairs, which may be potential DCAs, generated by the drug class-drug class interaction method. Methods: Eleven additive/synergistic and one antagonistic drug class-drug class interaction groups were identified. By combining drugs of two interacting drug class groups, numerous DDI pairs were made. The status and severity of DDI pairs were examined using Lexicomp and Micromedex. Also, the DCA listing rate was calculated. Results: Among 258 DDI pairs generated by the drug class-drug class interaction method, only 142 pairs were identified as official DCA pairs by the MFDS. One hundred and four pairs were identified as potential DCA pairs to be listed. QT prolonging agents-QT prolonging agents, triptans-ergot alkaloids, tricyclic antidepressants-monoamine oxidase inhibitors, and dopamine agonists-dopamine antagonists were identified as drug class-drug class interaction groups which have less than 50 % DCA listing rate. Conclusion: To improve the clinicians’ adaptability to DCA alerts, the list of DCA pairs needs to be continuously updated.
Abstract
Objectives: Drug utilization review program in Korea has provided ‘drug combinations to avoid (DCA)’ alerts to physicians and pharmacists to prevent potential adverse drug events or inappropriate drug use. Seven hundred and six DCA pairs have been announced officially by the Ministry of Food and Drug Safety (MFDS) by March, 2015. Some DCA pairs could be grouped based on the drug interaction mechanism and its consequences. This study aimed to investigate the drug-drug interaction (DDI) pairs, which may be potential DCAs, generated by the drug class-drug class interaction method. Methods: Eleven additive/synergistic and one antagonistic drug class-drug class interaction groups were identified. By combining drugs of two interacting drug class groups, numerous DDI pairs were made. The status and severity of DDI pairs were examined using Lexicomp and Micromedex. Also, the DCA listing rate was calculated. Results: Among 258 DDI pairs generated by the drug class-drug class interaction method, only 142 pairs were identified as official DCA pairs by the MFDS. One hundred and four pairs were identified as potential DCA pairs to be listed. QT prolonging agents-QT prolonging agents, triptans-ergot alkaloids, tricyclic antidepressants-monoamine oxidase inhibitors, and dopamine agonists-dopamine antagonists were identified as drug class-drug class interaction groups which have less than 50 % DCA listing rate. Conclusion: To improve the clinicians’ adaptability to DCA alerts, the list of DCA pairs needs to be continuously updated.
참고문헌 (14)
- Sandusky M, "Michigan drug utilization review and OBRA 90", Mich Med, 92, pp.38~39 (1993)
- Heo JH., "Evaluation of the pilot program on the real-time drug utilization review system in South Korea.", Int J Med Inform (2013)
- 박지영, "병용금기와 의약품 사용평가", 대한의사협회지, 55(5), pp.484~490 (2012), 대한의사협회[DOI]
- "Yakup Shinmoon" (2003)[URL]
- "Korean drug utilization review system" (2014)[URL]
- "Korea Institute of Drug Safety & Risk Management" (2015)[URL]
- "Ministry of Food and Drug Safety" (2015)[URL]
- Cascorbi I., "Drug interactions--principles, examples and clinical consequences", Dtsch Arztebl Int, 109, pp.546~555 (2012)
- Strandell J., "Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database", Eur J Clin Pharm, 67, pp.633~641 (2011)
- "Drug interactions result from a number of underlying pharmacokinetic and pharmacodynamic mechanisms", Drugs Ther Perspect, 29, pp.217~222 (2013)
- Thompson R, "PPI therapy : Clopidrogel-PPI drug interaction may not be a class effect", Nat Rev Gastroenterol Hepatol, 8(6), pp.302~ (2011)
- Rolan PE, "Drug Interactions with Triptans", CNS Drugs, 26, pp.949~957 (2012)
- Mehrotra N., "The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy", Int J Impot Res, 19, pp.253~264 (2007)
- Paterno MD., "Tiering drug-drug interaction alerts by severity increases compliance rates", J Am Med Inform Assoc, 16, pp.40~46 (2009)